Heron Therapeutics, Inc. reported that on October 13, 2025, stockholders approved two proposals regarding the issuance of shares based on the conversion of certain convertible notes and preferred stock, which may exceed 19.99% of the outstanding shares. A total of 183,314,409 shares were available for voting, with significant majority votes for both proposals (Proposal 1: 89,632,206 in favor; Proposal 2: 91,534,602 in favor).